| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
169,410,000 |
| Market
Cap: |
97.83(M) |
| Last
Volume: |
3,856,623 |
Avg
Vol: |
3,845,860 |
| 52
Week Range: |
$0.35 - $0.885 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Inovio Pharmaceuticals is a biotechnology company focused on bringing the designed deoxyribonucleic acid (DNA) medicines and vaccines to help protect people from infectious diseases, including COVID-19, and to help treat people with cancer, and conditions associated with human papillomavirus. Co.'s DNA medicines pipeline is comprised of three types of product candidates: prophylactic DNA vaccines, therapeutic DNA immunotherapies, and DNA encoded monoclonal and bispecific antibodies, all of which utilize the two components of Co.'s integrated platform, SynCon® and CELLECTRA®. Co. is evaluating the feasibility of, conducting or planning clinical studies of its DNA medicines.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
5,700 |
49,676 |
| Total Sell Value |
$0 |
$0 |
$3,192 |
$85,601 |
| Total People Sold |
0 |
0 |
1 |
3 |
| Total Sell Transactions |
0 |
0 |
1 |
7 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kies Peter |
CFO |
• – – |
2019-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,433 |
116,196 |
|
- |
|
| Humeau Laurent |
Chief Scientific Officer |
• – – |
2019-03-10 |
4 |
D |
$3.34 |
$3,166 |
D/D |
(948) |
25,833 |
|
- |
|
| Humeau Laurent |
Chief Scientific Officer |
• – – |
2019-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,812 |
26,781 |
|
- |
|
| Kim Jong Joseph |
Chief Executive Officer |
• • – |
2019-03-10 |
4 |
D |
$3.34 |
$100,547 |
D/D |
(30,104) |
2,511,055 |
|
- |
|
| Kim Jong Joseph |
Chief Executive Officer |
• • – |
2019-03-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
105,700 |
2,541,159 |
|
- |
|
| Weiner David B. |
Director |
– • – |
2019-03-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,333 |
793,625 |
|
- |
|
| Kies Peter |
CFO |
• – – |
2019-03-09 |
4 |
D |
$3.34 |
$28,694 |
D/D |
(8,591) |
95,763 |
|
- |
|
| Kies Peter |
CFO |
• – – |
2019-03-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,000 |
104,354 |
|
- |
|
| Humeau Laurent |
Chief Scientific Officer |
• – – |
2019-03-09 |
4 |
D |
$3.34 |
$2,999 |
D/D |
(898) |
23,969 |
|
- |
|
| Humeau Laurent |
Chief Scientific Officer |
• – – |
2019-03-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,666 |
24,867 |
|
- |
|
| Kim Jong Joseph |
Chief Executive Officer |
• • – |
2019-03-09 |
4 |
D |
$3.34 |
$54,539 |
D/D |
(16,329) |
2,435,459 |
|
- |
|
| Kim Jong Joseph |
Chief Executive Officer |
• • – |
2019-03-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
57,333 |
2,451,788 |
|
- |
|
| Humeau Laurent |
Chief Scientific OfficerOffice |
• – – |
2019-03-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
22,201 |
|
- |
|
| Kim Jong Joseph |
Chief Executive Officer |
• • – |
2019-03-05 |
4 |
D |
$3.61 |
$123,242 |
D/D |
(34,139) |
2,394,455 |
|
- |
|
| Kim Jong Joseph |
Chief Executive Officer |
• • – |
2019-03-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
120,100 |
2,428,594 |
|
- |
|
| Weiner David B. |
Director |
– • – |
2019-03-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,667 |
778,292 |
|
- |
|
| Bagarazzi Mark |
Chief Medical Officer |
• – – |
2019-03-05 |
4 |
D |
$3.61 |
$30,353 |
D/D |
(8,408) |
100,672 |
|
- |
|
| Bagarazzi Mark |
Chief Medical Officer |
• – – |
2019-03-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
27,567 |
109,080 |
|
- |
|
| Kies Peter |
CFO |
• – – |
2019-03-05 |
4 |
D |
$3.61 |
$37,187 |
D/D |
(10,301) |
79,354 |
|
- |
|
| Kies Peter |
CFO |
• – – |
2019-03-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
27,567 |
89,655 |
|
- |
|
| Dhillon Avtar S |
Director |
– • – |
2018-12-06 |
4 |
OE |
$2.00 |
$50,000 |
D/D |
25,000 |
106,002 |
|
- |
|
| Yarno Wendy L |
Director |
– • – |
2018-12-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,090 |
4,090 |
|
- |
|
| Kies Peter |
CFO |
• – – |
2018-11-29 |
4 |
S |
$5.28 |
$52,805 |
D/D |
(10,001) |
62,088 |
|
- |
|
| Kies Peter |
CFO |
• – – |
2018-11-29 |
4 |
OE |
$2.00 |
$20,002 |
D/D |
10,001 |
72,089 |
|
- |
|
| Kim Jong Joseph |
Chief Executive Officer |
• • – |
2018-09-12 |
4 |
S |
$5.37 |
$263,452 |
D/D |
(49,060) |
2,308,494 |
|
- |
|
488 Records found
|
|
Page 10 of 20 |
|
|
